Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PhRMA Lists NAFTA Renegotiation Priorities For Better US Exports

Executive Summary

US pharmaceutical industry association PhRMA has laid out what it thinks should be priorities in the upcoming renegotiation of the North American Free Trade Agreement. It wants pricing and reimbursement systems that reward innovation and improved enforcement of patentability standards.

You may also be interested in...



Could Trump’s NAFTA Renegotiation Hit Canadian Drug Price Controls?

Thanks to forthcoming NAFTA renegotiations, the US could put Canada under pressure to rethink its plans to curb excessive pricing.

Canada Plans Drug Price Reductions By Changing Reference Country List

Canadian authorities are consulting on potential new measures for curbing high drug prices. One of these would extend the list of countries it uses for international price comparisons.

Pharma Patents Are Vulnerable In Canada As Lilly Loses NAFTA Challenge

Tribunal finds Lilly did not prove that Canada's promise utility doctrine discriminates against pharmaceutical patents; 25 pharma patents have been invalidated in past decade.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS120871

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel